Idoroenyi Amanam, MD, discusses real-world study of luspatercept in LR-MDS

In this video interview with Dr. Amanam, he discusses the results of an abstract presented at ASCO 2025 titled, “Real-world outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept (LUSPA) or 1L erythropoiesis-stimulating agents (ESA) in the US.